Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice

被引:263
作者
Gomeza, J
Zhang, L
Kostenis, E
Felder, C
Bymaster, F
Brodkin, J
Shannon, H
Xia, B
Deng, CX
Wess, J
机构
[1] NIDDKD, Bioorgan Chem Lab, Bethesda, MD 20892 USA
[2] NIDDKD, Biochem & Metab Lab, Bethesda, MD 20892 USA
[3] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
D O I
10.1073/pnas.96.18.10483
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Muscarinic acetylcholine receptors (M-1-M-5) regulate many key functions of the central and peripheral nervous system. Primarily because of the lack of receptor subtype-selective ligands, the precise physiological roles of the individual muscarinic receptor subtypes remain to be elucidated; Interestingly, the M-4 receptor subtype is expressed abundantly in the striatum and various other forebrain regions. To study its potential role in the regulation of locomotor activity and other central functions, we used gene-targeting technology to create mice that lack functional M-4 receptors. Pharmacologic analysis of M-4 receptor-deficient mice indicated that M-4 receptors are not required for muscarinic receptor-mediated analgesia, tremor, hypothermia, and salivation. Strikingly, M-4 receptor-deficient mice showed an increase in basal locomotor activity and greatly enhanced locomotor responses (as compared with their wild-type littermates) after activation of D1 dopamine receptors. These results indicate that M-4 receptors exert inhibitory control on D1 receptor-mediated locomotor stimulation, probably at the level of striatal projection neurons where the two receptors are coexpressed at high levels. Our findings offer new perspectives for the treatment of Parkinson's disease and other movement disorders that are characterized by an imbalance between muscarinic cholinergic and dopaminergic neurotransmission.
引用
收藏
页码:10483 / 10488
页数:6
相关论文
共 41 条
[1]  
[Anonymous], TRENDS NEUROSCI
[2]  
BERNARD V, 1992, J NEUROSCI, V12, P3591
[3]  
BROWN JH, 1996, PHARMACOL BASIS THER, P141
[4]   D1 AND D2 RECEPTOR ANTAGONISTS DIFFERENTLY AFFECT COCAINE-INDUCED LOCOMOTOR HYPERACTIVITY IN THE MOUSE [J].
CABIB, S ;
CASTELLANO, C ;
CESTARI, V ;
FILIBECK, U ;
PUGLISIALLEGRA, S .
PSYCHOPHARMACOLOGY, 1991, 105 (03) :335-339
[5]   MUSCARINIC RECEPTORS - CHARACTERIZATION, COUPLING AND FUNCTION [J].
CAULFIELD, MP .
PHARMACOLOGY & THERAPEUTICS, 1993, 58 (03) :319-379
[6]   Fibroblast growth factor receptor 3 is a negative regulator of bone growth [J].
Deng, CX ;
WynshawBoris, A ;
Zhou, F ;
Kuo, A ;
Leder, P .
CELL, 1996, 84 (06) :911-921
[7]  
DORJE F, 1991, J PHARMACOL EXP THER, V256, P727
[8]  
Ellis JL, 1999, J PHARMACOL EXP THER, V288, P1143
[9]  
FARRELL CB, 1995, J NEUROCHEM, V65, P1124
[10]   D1 AND D2 DOPAMINE RECEPTOR REGULATED GENE-EXPRESSION OF STRIATONIGRAL AND STRIATOPALLIDAL NEURONS [J].
GERFEN, CR ;
ENGBER, TM ;
MAHAN, LC ;
SUSEL, Z ;
CHASE, TN ;
MONSMA, FJ ;
SIBLEY, DR .
SCIENCE, 1990, 250 (4986) :1429-1432